Paradis PE[au] - Search Results

Year	Number of Results
2007	2
2008	2
2009	3
2010	3
2012	3
2014	1
2023	0

1

The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.

Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE. Duh MS, et al. Among authors: paradis pe. Expert Opin Pharmacother. 2009 Oct;10(14):2317-28. doi: 10.1517/14656560903140525. Expert Opin Pharmacother. 2009. PMID: 19663636 Review.

2

The risks and costs of multiple-generic substitution of topiramate.

Duh MS, Paradis PE, Latrémouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J. Duh MS, et al. Among authors: paradis pe. Neurology. 2009 Jun 16;72(24):2122-9. doi: 10.1212/WNL.0b013e3181aa5300. Neurology. 2009. PMID: 19528520

3

Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.

Manjunath R, Paradis PE, Parisé H, Lafeuille MH, Bowers B, Duh MS, Lefebvre P, Faught E. Manjunath R, et al. Among authors: paradis pe. Neurology. 2012 Oct 30;79(18):1908-16. doi: 10.1212/WNL.0b013e318271f77e. Epub 2012 Oct 17. Neurology. 2012. PMID: 23077014

4

Economic burden associated with the use of generic antiepileptic drugs in the United States.

Helmers SL, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latrémouille-Viau D, Lefebvre P, Labiner DM. Helmers SL, et al. Among authors: paradis pe. Epilepsy Behav. 2010 Aug;18(4):437-44. doi: 10.1016/j.yebeh.2010.05.015. Epub 2010 Jun 30. Epilepsy Behav. 2010. PMID: 20580619

5

Generic antiepileptic drugs and associated medical resource utilization in the United States.

Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latrémouille-Viau D, Lefebvre P, Helmers SL. Labiner DM, et al. Among authors: paradis pe. Neurology. 2010 May 18;74(20):1566-74. doi: 10.1212/WNL.0b013e3181df091b. Epub 2010 Apr 14. Neurology. 2010. PMID: 20393142

6

Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.

LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O. LeLorier J, et al. Among authors: paradis pe. Neurology. 2008 May 27;70(22 Pt 2):2179-86. doi: 10.1212/01.wnl.0000313154.55518.25. Neurology. 2008. PMID: 18505997 Clinical Trial.

7

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.

Paradis PE, Latrémouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS. Paradis PE, et al. Curr Med Res Opin. 2009 Jul;25(7):1793-805. doi: 10.1185/03007990903044374. Curr Med Res Opin. 2009. PMID: 19505202

8

Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.

LeLorier J, Duh MS, Paradis PE, Latrémouille-Viau D, Lefebvre P, Manjunath R, Sheehy O. LeLorier J, et al. Among authors: paradis pe. Curr Med Res Opin. 2008 Apr;24(4):1069-81. doi: 10.1185/030079908x280572. Epub 2008 Feb 29. Curr Med Res Opin. 2008. PMID: 18315941

9

Economic impact of delays in listing decisions by provincial drug plans after a positive Common Drug Review recommendation: the case of a smoking-cessation treatment.

Paradis PE, Mishagina N, Carter V, Raymond V. Paradis PE, et al. Healthc Q. 2012;15(2):52-60. doi: 10.12927/hcq.2012.22912. Healthc Q. 2012. PMID: 22688206

10

Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.

Andermann F, Duh MS, Gosselin A, Paradis PE. Andermann F, et al. Among authors: paradis pe. Epilepsia. 2007 Mar;48(3):464-9. doi: 10.1111/j.1528-1167.2007.01007.x. Epilepsia. 2007. PMID: 17346246 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results